[1]
Penman ID, Lees CW. In: Davidson's Principles and Practice of Medicine, 22nd ed. Walker, BR, Colledge, NR, Ralston, SH, Penman, ID, Eds.;
Churchill Livingstone/Elsevier: Edinburgh; New York, 2014, pp 837-920.
[3]
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018; 390: 2769-78.
[4]
Cui G, Yuan A. A systematic review of epidemiology and risk factors associated with chinese inflammatory bowel disease. Front Med (Lausanne) 2018; 5: 183.
[5]
Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: A systematic review. Scand J Gastroenterol 2018; 53: 1-7.
[6]
Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: Imitations and complications. Lancet Gastroenterol Hepatol 2018; 3: 644-53.
[7]
Shivashankar R, Lichtenstein GR. Mimics of inflammatory bowel disease. Inflamm Bowel Dis 2018; 24: 2315-21.
[8]
Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn 2018; 18: 867-86.
[9]
Masaki T, Kishiki T, Kojima K, Asou N, Beniya A, Matsuoka H. Recent trends (2016-2017) in the treatment of inflammatory bowel disease. Ann Gastroenterol Surg 2018; 2: 282-8.
[10]
Panes J, Salas A. Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease. J Crohn’s Colitis 2018; 12: S633-40.
[11]
Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc 2018; 118(7): 1083-92.
[12]
Trivedi PJ, Adams DH. Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; Pitfalls and Promise. J Crohns Colitis 2018; 12: S641-52.
[13]
McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: The gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther 2018; 47: 26-42.
[14]
Witkowski M, Witkowski M, Gagliani N, Huber S. Recipe for IBD: Can we use food to control inflammatory bowel disease? Semin Immunopathol 2018; 40: 145-56.
[15]
Limketkai BN, Wolf A, Parian AM. Nutritional interventions in the patient with inflammatory bowel disease. Gastroenterol Clin North Am 2018; 47: 155-77.
[16]
Rufino MN, Aleixo GFP, Trombine-Batista IE, et al. Systematic review and meta-analysis of preclinical trials demonstrate robust beneficial effects of prebiotics in induced inflammatory bowel disease. J Nutr Biochem 2018; 62: 1-8.
[17]
Rahman SU, Li Y, Huang Y, et al. Treatment of inflammatory bowel disease via green tea polyphenols: Possible application and protective approaches. Inflammopharmacology 2018; 26: 319-30.
[18]
de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: New findings and perspectives. J Crohn’s Colitis 2018; 12: 610-20.
[19]
Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: Prospects for clinical application of NUDT15 genotyping. J Gastroenterol 2018; 53: 172-80.
[20]
Lu MJ, Qiu XY, Mao XQ, Li XT, Zhang HJ. Systematic review with meta-analysis: Thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018; 47: 318-31.
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
17
2
1